This seems likely, only because they did extend CD12 and there is no announced protocol approval from the fda for any other different covid trials. What I am wondering is if the problem with the 2 dose limit is altered? Or, do they shorten the 28 days to 14? I guess extending cd12 until we get statistical power is quicker than starting a whole new trial. It could also explain the lack of an EUA, could be the FDA realizes how close the data is and wants to just move a little further to an approval instead of going in another direction.